You can watch LIXTW and buy or sell other stocks, options, and ETFs commission-free!
Lixte Biotechnology Holdings, Inc. engages in the development of drugs for cancer treatment. The firm uses biomarker technology to identify enzyme targets associated with serious common diseases and designs novel compounds to attack those targets. Its product pipeline is primarily focused on inhibitors of protein phosphatases, used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers, and encompasses two major categories of compounds at various stages of pre-clinical and clinical development that the Company believes have broad therapeutic potential not only for cancer but also for other debilitating and life-threatening diseases. The company was founded by John S. Kovach and Robert B. Royds on August 9, 2005 and is headquartered in East Setauket, NY. The listed name for LIXTW is Lixte Biotechnology Holdings, Inc. Warrants.
John S. Kovach, MD
East Setauket, New York
52 Week High
52 Week Low